Laboratory Corporation of America Holdings (LH)

Market Cap	16.69B
Revenue (ttm)	12.16B
Net Income (ttm)	418.00M
Shares Out	84.10M
EPS (ttm)	4.77
PE Ratio	41.59
Forward PE	13.00
Dividend	$2.88 (1.45%)
Ex-Dividend Date	May 28, 2024

Volume	913,477
Open	197.08
Previous Close	198.35
Day's Range	197.01 - 200.16
52-Week Range	179.59 - 234.09
Beta	1.00
Analysts	Buy
Price Target	242.00 (+21.98%)
Earnings Date	Apr 25, 2024

About LH

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepa...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1971
• Employees: 67,000
• Stock Exchange: NYSE
• Ticker Symbol: LH

Financial Performance

In 2023, LH's revenue was $12.16 billion, an increase of 2.51% compared to the previous year's $11.86 billion. Earnings were $418.00 million, a decrease of -67.32%.

Analyst Forecast

According to 13 analysts, the average rating for LH stock is "Buy." The 12-month stock price forecast is $242.0, which is an increase of 21.98% from the latest price.

Price Target

$242.0

(21.98% upside)

Analyst Consensus: Buy